Gracell Biotechnologies Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was CNY 146.31 million compared to CNY 96.22 million a year ago. Basic loss per share from continuing operations was CNY 2.15 compared to CNY 1.45 a year ago. Diluted loss per share from continuing operations was CNY 2.15 compared to CNY 1.45 a year ago.
For the six months, net loss was CNY 304.89 million compared to CNY 193.88 million a year ago. Basic loss per share from continuing operations was CNY 4.5 compared to CNY 3.05 a year ago. Diluted loss per share from continuing operations was CNY 4.5 compared to CNY 3.05 a year ago.